Search results
U.K. Tests World-First Personalized Skin Cancer Vaccine
Forbes· 6 days agoBritish patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a...
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
Reuters· 6 days ago, opens new tab on Thursday raised its annual profit and revenue forecast on the back of strong...
Merck’s first-quarter results beat expectations amid healthy vaccine-sales growth
Market Watch· 6 days agoMerck & Co. Inc. on Thursday reported first-quarter results that beat analysts’ expectations amid...
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
FOX 59 Indianapolis· 4 hours agoUSA News Group – An alarming trend is happening around the world, where tens of millions of...
Merck stock target raised on strong Q1 results By Investing.com
Investing.com· 5 days agoThe adjustment comes in the wake of Merck's first-quarter results, which not only featured a robust...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 6 days agoThe Zacks Consensus Estimate for 2024 EPS has declined from $11.13 per share to $11.12 over the past...
Man’s ‘bump on head’ turns out to be sign of skin cancer
Yahoo Life UK· 5 days agoYoung, who had the melanoma growth cut out of his scalp last August, is one of the first patients to...
Merck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 1 day agoMerck & Co., Inc. (NYSE:MRK) Q1 2024 Earnings Call Transcript April 25, 2024 Merck & Co., Inc. beats...
Merck stock rises on sales of its blockbuster cancer drug Keytruda
Quartz· 6 days agoMerck’s stock jumped 3% to about $130 during Thursday morning trading after the New Jersey-based pharmaceutical company reported higher than expected sales of its blockbuster cancer drug < ...
British patients test world’s first personalised mRNA jab for melanoma
PA Media: Science via Yahoo News· 6 days agoPhase 2 data, published in December, found that people with serious high-risk melanomas who received...